RHYTHM PHARMACEUTICALS, INC.
Extracted from this filing and checked against the source text.
RHYTHM PHARMACEUTICALS, INC. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers at the 2023-06-21 meeting.
Item 3 – Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.View on SEC.gov
RHYTHM PHARMACEUTICALS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm at the 2023-06-21 meeting.
Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.View on SEC.gov
RHYTHM PHARMACEUTICALS, INC. shareholders approved Election of three Class III Directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-06-21 meeting.
Item 1 - Election of three Class III Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.